SRPT
Sarepta Therapeutics, Inc. · NASDAQ
- Sector Health Technology
- Industry Pharmaceuticals: Major
- Website arepta.com
- Employees(FY) 1162
- ISIN US8036071004
Performance
-1.22%
1W
+2.35%
1M
-1.95%
3M
+1.53%
6M
+29.08%
YTD
+41.91%
1Y
Profile
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; and AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program that is under Phase 1/2a clinical trial; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Selecta Biosciences; Hansa Biopharma; Lysogene; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
Technical Analysis of SRPT 2024-12-12
Technical Scores and Rating
Moving Average Score
Oscillator Score
Technical Rating
Recent News & Updates
- 2024-12-06 11:31
- 2024-12-03 19:00
SRPT: Lowering target price to $101.00(Argus Research)
- 2024-12-03 06:24
ARWR: License and Collaboration Deal with Sarepta Includes $825 Million Upon Closing…(Zacks Small Cap Research)
- 2024-11-30 06:00
- 2024-11-29 16:10
- 2024-11-29 13:59
- 2024-11-29 03:10
- 2024-11-28 08:15
- 2024-11-27 11:31
- 2024-11-27 09:55
- 2024-11-27 07:21
- 2024-11-27 07:20
- 2024-11-27 06:00
Sarepta rebuilds drug pipeline with Arrowhead deal(BioPharma Dive)
- 2024-11-27 04:33
Arrowhead and Sarepta link for rare genetic disease treatments(Pharmaceutical Technology)
- 2024-11-26 19:00
SRPT: Raising target price to $104.00(Argus Research)
- 2024-11-26 16:05
Arrowhead Pharma, Sarepta TX ink new gene therapy deal(Yahoo Finance Video)
- 2024-11-26 13:31
Sector Update: Health Care(MT Newswires)
- 2024-11-26 10:55
Arrowhead, Sarepta Skyrocket After Duo Inks A Whopping $11.38 Billion Deal(Investor's Business Daily)
- 2024-11-26 08:14
- 2024-11-26 07:00
- 2024-11-25 20:06
- 2024-11-25 18:00
- 2024-11-25 18:00
- 2024-11-22 13:05
High Growth Tech Stocks to Watch in November 2024(Simply Wall St.)
- 2024-11-15 12:26
- 2024-11-13 05:25
- 2024-11-12 19:00
SRPT: Lowering target price to $91.00(Argus Research)
- 2024-11-12 06:56
- 2024-11-08 06:57
- 2024-11-07 09:19
Page 1 of 10
previousnext
Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.